CCL2 and dementia: Our results indicated that the dementia marker MCP-1 was effective in reducing cognitive impairment on community-dwelling individuals of various ages after 4 weeks of treatment; (50–59 years; * p < 0.05), (60–69 years; *** p < 0.001), and (70–79 years; ** p < 0.01) are shown Figure S5.